dNK:IO REV-ERB Antagonists

About NK:IO

NK:IO is a preclinical-stage biotech developing novel NK cell and small molecule immunotherapies for cancer. The company has built three proprietary technology platforms—wNK:IO, eNK:IO, and dNK:IO—aimed at overcoming the key limitations of NK cell therapies: poor expansion and rapid exhaustion. Backed by prominent UK seed investors and founded on research from Imperial College, NK:IO is targeting hard-to-treat cancers like ovarian cancer with its enhanced and engineered NK cell approaches.

Therapeutic Areas